Gentian Diagnostics ASFRA:6FK +3.58%73 Days Payable is 115.45 as of Jun. 2026, which is 129% above its 10-year median of 50.45. GuruFocus rates FRA:6FK with a GF Score™ of 73/100 and a GF Value™ of €5.19 (Significantly Undervalued). Among 796 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks better than 67.96% on this metric.
The historical rank and industry rank for Gentian Diagnostics AS's Days Payable or its related term are showing as below:
FRA:6FK'
s Days Payable Range Over the Past 10 Years
Min: 20.97 Med: 50.45 Max: 222.86
Current: 106.65
During the past 13 years, Gentian Diagnostics AS's highest Days Payable was 222.86. The lowest was 20.97. And the median was 50.45.
FRA:6FK's Days Payable is ranked better than 67.96% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 67.97
vs FRA:6FK: 106.65
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Gentian Diagnostics AS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Days Payable distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Gentian Diagnostics AS's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS (FRA:6FK) has a Days Payable of 115.45 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gentian Diagnostics AS and its competitors. This is 129% above median its historical median of 50.45. Over the past decade, Gentian Diagnostics AS's Days Payable has ranged from 20.97 to 222.86. According to the industry distribution chart, Gentian Diagnostics AS ranks #255 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 32%.
Is Gentian Diagnostics AS's Days Payable too high?
Gentian Diagnostics AS's current Days Payable of 115.45 is 129% above median its 10-year median of 50.45. Over the past 10 years, this metric has ranged from a low of 20.97 to a high of 222.86. The Medical Devices & Instruments industry median Days Payable is 67.97. Gentian Diagnostics AS's value of 115.45 is 69.9% above this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #255 out of 796 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Gentian Diagnostics AS has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #255 out of 796 companies for Days Payable. This puts Gentian Diagnostics AS in the upper half of its industry. The industry median Days Payable is 67.97. Gentian Diagnostics AS's value of 115.45 is 69.9% above this benchmark. Historically, Gentian Diagnostics AS's own Days Payable has ranged from 20.97 to 222.86 over the past decade. While the company's 10-year median is 50.45 vs. the industry median of 67.97, Gentian Diagnostics AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current Days Payable of 115.45 is 69.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gentian Diagnostics AS and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current Days Payable is 115.45, which is 129% above median its own 10-year median of 50.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (FRA:6FK) is currently considered Significantly Undervalued. The stock's GF Value™ is €5.19, compared to a current price of €3.47 — trading 33.1% below its estimated fair value. The current Days Payable is 115.45, which is 129% above median its 10-year median of 50.45 and 69.9% above the Medical Devices & Instruments industry median of 67.97. Gentian Diagnostics AS's overall GF Score™ is 73/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Gentian Diagnostics AS (FRA:6FK), the current Days Payable is 115.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (FRA:6FK) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of €3.47 is trading 33.1% below its estimated GF Value™ of €5.19.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for FRA:6FK:
Days Payable: 115.45 (129% above median its 10-year median of 50.45)
GF Value™: €5.19 vs. price of €3.47 (33.1% below fair value)
Industry Position: 69.9% above the Medical Devices & Instruments median (#255 of 796)
No single metric tells the full story. See the FRA:6FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
73GF Score
Get the complete analysis for FRA:6FK
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6FK has been successfully added to your 
